Methylphenidate, a psycho-stimulant drug, also known by its 1948 trademarked name of Ritalin, could be useful in the treatment of excessive daytime sleepiness (EDS) for DM1 patients, according to a recent study conducted by The Department of Human Genetics at the Centre Hospitalier Universitaire de Quebec in Quebec City, Canada.
The Myotonic Dystrophy Foundation (MDF) is pleased to announce its most recent round of Fund-A-Fellow postdoctoral fellowship research grant awards. In January 2013, MDF awarded two $100,000 grants to postdoctoral Fellows working in universities and research facilities
MDF takes its role as an advocate for the myotonic dystrophy community very seriously; we are committed to increasing visibility and understanding of DM, improving the quality of life of people living with this disease, and doing our part to accelerate research progress toward treatments and a cure for DM.
The Myotonic Dystrophy Foundation turned 5 this year! It was a notable milestone for a young patient organization, and one that saw enormous growth and advancement in a number of key areas,
A generic cardiovascular drug called mexiletine, initially developed to treat heart rhythm abnormalities, appears to hold some potential for treating muscle stiffness and other symptoms of non-dystrophic myotonias (NDMs),